The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
In its second-quarter 2026 investor letter, Harbor Mid Cap Value Fund highlighted Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as a newly added position. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops and commercializes medicines to treat various diseases. On September 04, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $827.72 per share, reflecting a market capitalization of $85.21 billion. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted a one‑month return of 2.43%, while its shares gained 48.22% over the past 52 weeks.
Harbor Mid Cap Value Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q2 2026 investor letter:
"We added to our position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotech company in the Health Care sector. The stock ranks high on multiple cash flow and forecasted earnings measures — two of our most important measures of valuation. While the company pays a below-average dividend, Regeneron has been buying back stock, which we view positively. Price momentum over the past 12 months has been strong. In addition, several indicators of operating momentum also are attractive with improving operating margins and growth in sales. Overall, the stock ranks in the top 10% in our stock-ranking universe, which led to the second quarter purchase."
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 63 hedge fund portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the second quarter, down from 72 in the previous quarter. While we acknowledge the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.